List of Figures

Figure 1: Clinical Presentations of PsA
Figure 2: Classification of PsA
Figure 3: Risk Factors
Figure 4: Role of Obesity and Risk of Cardiovascular Comorbidities in PsA patients
Figure 5: Key cell Types and Secretion of key Inflammatory Mediators in PsA
Figure 6: Adaptive and Innate Immune Cells and Activated Pathways in PsA
Figure 7: Diagnosis of PsA
Figure 8: Radiographic Features of PsA
Figure 9: Differential Diagnosis
Figure 10: Pharmacologic, Non-pharmacologic, and Symptomatic Therapies for PsA
Figure 11: The EULAR 2019 Algorithm for Treatment of PsA With Pharmacological Non-topical Treatments
Figure 12: PsA Treatment Pathway Following Inadequate Response to DMARDs (NICE)
Figure 13: Total Prevalent Cases of PsA in the 7MM in 000’s (2019–2032)
Figure 14: Prevalent cases of PsA in the United States in 000’s (2019–2032)
Figure 15: Diagnosed Cases of PsA in the United States in 000’s (2019–2032)
Figure 16: Gender-specific cases of PsA in the United States in 000’s (2019–2032)
Figure 17: Age-specific Cases of PsA in the United States in 000’s (2019–2032)
Figure 18: Severity-specific Cases of PsA in the United States in 000’s (2019–2032)
Figure 19: Prevalent Cases of PsA in the EU5 in 000’s (2019–2032)
Figure 20: Diagnosed cases of PsA in Germany in 000’s (2019–2032)
Figure 21: Gender-specific cases of PsA in Germany in 000’s (2019–2032)
Figure 22: Age-specific Cases of PsA in Germany in 000’s (2019–2032)
Figure 23: Severity-specific Cases of PsA in Germany in 000’s (2019–2032)
Figure 24: Diagnosed cases of PsA in France (2019–2032)
Figure 25: Gender-specific cases of PsA in France in 000’s (2019–2032)
Figure 26: Age-specific Cases of PsA in France in 000’s (2019–2032)
Figure 27: Severity-specific Cases of PsA in France (2019–2032)
Figure 28: Diagnosed cases of PsA in Italy in 000’s (2019–2032)
Figure 29: Gender-specific cases of PsA in Italy in 000’s (2019–2032)
Figure 30: Age-specific Cases of PsA in Italy in 000’s (2019–2032)
Figure 31: Severity-specific Cases of PsA in Italy in 000’s (2019–2032)
Figure 32: Diagnosed cases of PsA in Spain in 000’s (2019–2032)
Figure 33: Gender-specific cases of PsA in Spain in 000’s (2019–2032)
Figure 34: Age-specific Cases of PsA in Spain in 000’s (2019–2032)
Figure 35: Severity-specific Cases of PsA in Spain in 000’s (2019–2032)
Figure 36: Diagnosed cases of PsA in the UK in 000’s (2019–2032)
Figure 37: Gender-specific cases of PsA in the UK in 000’s (2019–2032)
Figure 38: Age-specific Cases of PsA in the UK in 000’s (2019–2032)
Figure 39: Severity-specific Cases of PsA in the UK in 000’s (2019–2032)
Figure 40: Prevalent cases of PsA in Japan in 000’s (2019–2032)
Figure 41: Diagnosed Cases of PsA in Japan in thousands (2019–2032)
Figure 42: Gender-specific cases of PsA in Japan in 000’s (2019–2032)
Figure 43: Age-specific Cases of PsA in Japan in 000’s (2019–2032)
Figure 44: Severity-specific Cases of PsA in Japan in 000’s (2019–2032)
Figure 45: Total Market Size of PsA in the 7MM (2019–2032)
Figure 46: Market Size of PsA in the United States (2019–2032)
Figure 47: Market Size of PsA in the United States by Systemic Therapies (2019–2032)
Figure 48: Market Size of PsA in the United States by Products (2019–2032)
Figure 49: The EU5 Market Size of PsA (2019–2032)
Figure 50: Market Size of PsA in Germany by Systemic Therapies (2019–2032)
Figure 51: Market Size of PsA in Germany by Products (2019–2032)
Figure 52: Market Size of PsA in France by Systemic Therapies (2019–2032)
Figure 53: Market Size of PsA in France by Products (2019–2032)
Figure 54: Market Size of PsA in Italy by Systemic Therapies (2019–2032)
Figure 55: Market Size of PsA in Italy by Products (2019–2032)
Figure 56: Market Size of PsA in Spain by Systemic Therapies (2019–2032)
Figure 57: Market Size of PsA in Spain by Products (2019–2032)
Figure 58: Market Size of PsA in the UK by Systemic Therapies (2019–2032)
Figure 59: Market Size of PsA in the UK by Products (2019–2032)
Figure 60: Total Market Size of PsA in Japan (2019–2032)
Figure 61: Market Size of PsA in Japan by Systemic Therapies in USD Million (2019–2032)
Figure 62: Market Size of PsA in Japan by Products (2019–2032)

List of Tables

Table 1: Summary of PsA, Epidemiology, and Key Events (2019–2032)
Table 2: Role of HLA Genes in PsA
Table 3: Role of non-HLA Genes in PsA
Table 4: CASPAR Criteria
Table 5: Moll and Wright Classification
Table 6: Operational Definition of Classification of PsA
Table 7: Suggested Diagnostic Algorithm
Table 8: Clinical Characteristics of Different Types of Arthritis That can aid Differential Diagnosis
Table 9: 2018 ACR/NPF Recommendations for the Initial Treatment for Active PsA who are OSM? and Other Treatment-naive
Table 10: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With a TNFi Biologics
Table 11: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With an IL?17i or an IL?12/23i Biologics
Table 12: 2018 ACR/NPF Recommendations for PsA Including Treat?to?target, Active Axial Disease, Enthesitis, or Active IBD
Table 13: 2018 ACR/NPF Recommendations for PsA and Comorbidities, Including Concomitant Diabetes and Recurrent Serious Infections
Table 14: 2018 ACR/NPF Recommendations for Non-pharmacologic Interventions in Patients With Active PsA Regardless of Pharmacologic Treatment Status
Table 15: Summary of Differences in Recommendations
Table 16: 2019 EULAR Overarching Principles
Table 17: 2019 EULAR Recommendations for the Pharmacological Management of PsA
Table 18: Total Prevalent Cases of PsA in the 7MM in 000’s (2019–2032)
Table 19: Prevalent cases of PsA in the United States in 000’s (2019–2032)
Table 20: Diagnosed Cases of PsA in the United States in 000’s (2019–2032)
Table 21: Gender-specific Cases of PsA in the United States in 000’s (2019–2032)
Table 22: Age-specific Cases of PsA in the United States in 000’s (2019–2032)
Table 23: Severity-specific cases of PsA in the United States in 000’s (2019–2032)
Table 24: Prevalent Cases of PsA in the EU5 in 000’s (2019–2032)
Table 25: Diagnosed cases of PsA in Germany in 000’s (2019–2032)
Table 26: Gender-specific Cases of PsA in Germany in 000’s (2019–2032)
Table 27: Age-specific Cases of PsA in Germany in 000’s (2019–2032)
Table 28: Severity-specific cases of PsA in Germany in 000’s (2019–2032)
Table 29: Diagnosed cases of PsA in France (2019–2032)
Table 30: Gender-specific Cases of PsA in France in 000’s (2019–2032)
Table 31: Age-specific Cases of PsA in France in 000’s (2019–2032)
Table 32: Severity-specific cases of PsA in France (2019–2032)
Table 33: Diagnosed cases of PsA in Italy in 000’s (2019–2032)
Table 34: Gender-specific Cases of PsA in Italy in 000’s (2019–2032)
Table 35: Age-specific Cases of PsA in Italy in 000’s (2019–2032)
Table 36: Severity-specific cases of PsA in Italy in 000’s (2019–2032)
Table 37: Diagnosed cases of PsA in Spain in 000’s (2019–2032)
Table 38: Gender-specific Cases of PsA in Spain in 000’s (2019–2032)
Table 39: Age-specific Cases of PsA in Spain in 000’s (2019–2032)
Table 40: Severity-specific cases of PsA in Spain in 000’s (2019–2032)
Table 41: Diagnosed cases of PsA in the UK in 000’s (2019–2032)
Table 42: Gender-specific Cases of PsA in the UK in 000’s (2019–2032)
Table 43: Age-specific Cases of PsA in the UK in 000’s (2019–2032)
Table 44: Severity-specific cases of PsA in the UK in 000’s (2019–2032)
Table 45: Prevalent cases of PsA in Japan in 000’s (2019–2032)
Table 46: Diagnosed Cases of PsA in Japan in 000’s (2019–2032)
Table 47: Gender-specific Cases of PsA in Japan in 000’s (2019–2032)
Table 48: Age-specific Cases of PsA in Japan in 000’s (2019–2032)
Table 49: Severity-specific cases of PsA in Japan in 000’s (2019–2032)
Table 50: Key cross of marketed products
Table 51: Key cross of emerging drugs
Table 52: Bimekizumab, Clinical Trial Description, 2022
Table 53: Tildrakizumab, Clinical Trial Description, 2022
Table 54: Deucravacitinib, Clinical Trial Description, 2022
Table 55: Tildrakizumab, Clinical Trial Description, 2022
Table 56: Key cross of emerging drugs
Table 57: NDI-034858, Clinical Trial Description, 2022
Table 58: Neihulizumab, Clinical Trial Description, 2022
Table 59: Total Market Size of PsA in the 7MM in USD Million (2019–2032)
Table 60: FDA Approved Biosimilars for PsA
Table 61: Biosimilars in Development
Table 62: Weighted Score Based on Ranking
Table 63: Market Size of PsA in the United States in USD Million (2019–2032)
Table 64: Market Size of PsA in the United State by Systemic Therapies in USD Million (2019–2032)
Table 65: Market Size of PsA in the United State by Products in USD Million (2019–2032)
Table 66: The EU5 Market Size of PsA in USD Million (2019–2032)
Table 67: Market Size of PsA in Germany by Systemic Therapies in USD Million (2019–2032)
Table 68: Market Size of PsA in Germany by Products in USD Million (2019–2032)
Table 69: Market Size of PsA in France by Systemic Therapies in USD Million (2019–2032)
Table 70: Market Size of PsA in France by Products in USD Million (2019–2032)
Table 71: Market Size of PsA in Italy by Systemic Therapies in USD Million (2019–2032)
Table 72: Market Size of PsA in Italy by Products in USD Million (2019–2032)
Table 73: Market Size of PsA in Spain by Systemic Therapies in USD Million (2019–2032)
Table 74: Market Size of PsA in Spain by Products in USD Million (2019–2032)
Table 75: Market Size of PsA in the UK by Systemic Therapies in USD Million (2019–2032)
Table 76: Market Size of PsA in the UK by Products in USD Million (2019–2032)
Table 77: Total Market Size of PsA in Japan in USD Million (2019–2032)
Table 78: Market Size of PsA in Japan by Systemic Therapies in USD Million (2019–2032)
Table 79: Market Size of PsA in Japan by Products in USD Million (2019–2032)